Table 2.

Clinical characteristics and PD-L1 expression in concurrent gene alteration patients

Case	Gender	Age	Stage	Smoking	Gene type	PD-L1 expression	OS (month)
1	Male	43	IB	Yes	EGFR+PIK3CA	Yes	67+
2	Female	51	IIIA	No	RET+PIK3CA	Yes	42
3	Female	58	IIIA	No	EGFR+ALK	Yes	34
4	Male	74	IA	No	EGFR+PIK3CA	No	66+
5	Male	60	IIIA	Yes	KRAS+ALK	Yes	35+
6	Female	60	IB	No	EGFR+RET-M2	Yes	54
7	Female	60	IA	No	EGFR+PIK3CA	Yes	36+
8	Male	64	IIA	No	RET+PIK3CA	No	55
9	Male	69	IB	No	KRAS6+HER2	Yes	43+
10	Male	45	IIIA	Yes	KRAS+PIK3CA	Yes	25
11	Female	64	IIB	Yes	EGFR+HER2	No	46+
12	Female	75	IIIA	No	EGFR+PIK3CA	No	24+
13	Female	69	IIA	No	KRAS+PIK3CA	Yes	36
14	Female	49	IB	No	EGFR+HER2	Yes	48+
15	Female	55	IIB	Yes	ROS1+HER2	Yes	37+
16	Male	62	IB	Yes	EGFR+ALK	No	46
17	Male	55	IIIA	No	EGFR+PIK3CA	Yes	39
18	Female	68	IB	No	EGFR+PIK3CA	Yes	58+
19	Female	76	IB	No	ALK+RET-M16	No	28
20	Male	43	IB	No	EGFR+PIK3CA	Yes	55+
21	Male	59	IIIA	Yes	KRAS+PIK3CA	Yes	18+
22	Female	61	IB	No	EGFR+PIK3CA	Yes	66+
23	Female	68	IIA	No	EGFR+HER2	Yes	45
24	Male	62	IIIA	Yes	KRAS+HER2	Yes	16